// App-Quantinova.ai

e14552 : High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.

Researchers

Presenter

  • Ivan Victoria

Principal Investigators

  • Lydia Gaba

  • Margarita Viladot

  • Maria Jose Quevedo

  • Francisco Aya

  • Carme Font

  • Estela Pineda

  • Josep Llach

  • Aleix Prat

  • Ana Maria Arance Fernandez

Medical Centers

  • Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Gastroenterologia, Hospital Universitario Puerta de Hierro, Madrid, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved